Our data indicate that assessing intestinal expressions of formyl peptide receptors and annexin A1 might provide precious information on the disease activity and responsiveness to infliximab in inflammatory bowel disease patients. The gene discussed is ANXA1; the disease is inflammatory bowel disease.